Liquidia Technologies, Inc.

Vero Biotech Inc.

Robert Frank Roscigno

Benjamin Maynor

Jacob J Sprague

Brian T Farrer

David H Fine

Lewis J Rubin

Tammy Watts

A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

Dry powder treprostinil for the treatment of pulmonary hypertension

A method for treating pulmonary arterial hypertension in a patient can include determining whether a patient with pulmonary arterial hypertension has an enlarged right ventricle or right ventricular dysfunction, where the patient has previously been administered a prostanoid and weaning the patient off of the prostanoid if the patient does not have an enlarged right ventricle or right ventricular dysfunction.

Method of determining vasoreactivity using inhaled nitric oxide

Growing community of inventors

Melbourne Beach, FL, United States of America

Robert Frank Roscigno